MK-2060 + Placebo
Phase 1Completed 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Venous Thrombosis
Conditions
Venous Thrombosis
Trial Timeline
Oct 15, 2024 → Apr 18, 2025
NCT ID
NCT06582602About MK-2060 + Placebo
MK-2060 + Placebo is a phase 1 stage product being developed by Merck for Venous Thrombosis. The current trial status is completed. This product is registered under clinical trial identifier NCT06582602. Target conditions include Venous Thrombosis.
Hype Score Breakdown
Clinical
10
Activity
5
Company
10
Novelty
3
Community
2
Clinical Trials (6)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06582602 | Phase 1 | Completed |
| NCT05769595 | Phase 1 | Completed |
| NCT06843993 | Phase 1 | Completed |
| NCT05656040 | Phase 1 | Completed |
| NCT05027074 | Phase 2 | Completed |
| NCT03873038 | Phase 1 | Completed |
Competing Products
20 competing products in Venous Thrombosis